New Report Exposes Devastating Impact of Trump’s Budget on America’s Social Safety Net Programs
Innovating for the Public Good Reveals the Red Tape Barriers to Social Safety Net Programs,Increased by One Big Beautiful Bill...
Disability
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency...
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected...
Hearo Technologies and Smart Living Systems Announce Strategic Partnership to Transform Disability Support Nationwide
SPRINGFIELD, Mo., July 30, 2025 /PRNewswire/ -- Hearo Technologies and Smart Living Systems (SLS), the technology innovation arm of LADD, Inc.,...
Life Backup Plan by Galacxia, Inc Announces $45K in Funding to Expand Its AI-Powered Health and Safety App
Aliso Viejo, CA, July 30, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan by Galacxia, Inc, redefining how individuals and care...
Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
Data readout expected in Q1 2026MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and...
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of...
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging...
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo,...
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this NovemberTORONTO and...
Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the...
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong...
AnswersNow Launches Corporate Advisory Board to Advance Scale of Innovative Virtual Autism Platform
Board brings together diverse industry veterans representing insurers, educators, clinicians and healthcare providers to ensure a robust, practical approach to...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US...
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering...
Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical Trial
Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14,...